Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022350079> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W2022350079 endingPage "623" @default.
- W2022350079 startingPage "618" @default.
- W2022350079 abstract "Objective.To determine the efficacy of secondary chemotherapy after failure of initial treatment for high-risk gestational trophoblastic neoplasia.MethodsTwenty-six patients with high-risk gestational trophoblastic neoplasia based on WHO criteria who failed primary treatment or relapsed from remission and received secondary chemotherapy were identified from the records of the Brewer Trophoblastic Disease Center. Initial chemotherapy consisted of etoposide, high-dose methotrexate with folinic acid, actinomycin D, cyclophosphamide and vincristine (EMA-CO) in 10 patients and methotrexate/actinomycin D-based chemotherapy without etoposide in 16 patients. Secondary chemotherapy consisted mainly of platinum-etoposide combinations with methotrexate and actinomycin D (EMA-EP), bleomycin (BEP), or ifosfamide (VIP, ICE). Adjuvant surgery and radiotherapy were used in selected patients. Clinical response and survival as well as factors affecting survival were analyzed retrospectively.ResultsThe overall survival has 61.5% (16/26). Of the 10 patients who failed primary treatment with EMA-CO, 9 (90%) had complete clinical responses to secondary chemotherapy with EMA-EP (3) or BEP (6), and 6 (60%) were placed into lasting remission. Of the 16 patients who failed primary treatment with methotrexate/actinomycin D-based chemotherapy without etoposide, 10 (63%) had complete clinical responses to BEP (8), VIP (1) and ICE (1), and 10 (63%) achieved long-term remission. Adjuvant surgical procedures were performed on 15 patients as a component of their therapy; eight (73%) of 11 patients who underwent hysterectomy, five (62%) of eight patients who had pulmonary resections, and one patient who had wedge resection of resistant choriocarcinoma from the uterus survived. Survival was significantly influenced by both hCG level at the start of secondary therapy and sites of metastases.ConclusionPatients with persistent or recurrent high-risk gestational trophoblastic neoplasia who develop resistance to methotrexate-containing treatment protocols should be treated with drug combinations employing a platinum agent and etoposide with or without bleomycin or ifosfamide." @default.
- W2022350079 created "2016-06-24" @default.
- W2022350079 creator A5015842548 @default.
- W2022350079 creator A5086072634 @default.
- W2022350079 date "2005-05-01" @default.
- W2022350079 modified "2023-10-03" @default.
- W2022350079 title "Secondary chemotherapy for high-risk gestational trophoblastic neoplasia" @default.
- W2022350079 cites W1635080073 @default.
- W2022350079 cites W1929177538 @default.
- W2022350079 cites W1955563698 @default.
- W2022350079 cites W1968373373 @default.
- W2022350079 cites W1980400027 @default.
- W2022350079 cites W1980610432 @default.
- W2022350079 cites W1988014018 @default.
- W2022350079 cites W1992479357 @default.
- W2022350079 cites W2012831732 @default.
- W2022350079 cites W2025286523 @default.
- W2022350079 cites W2027652666 @default.
- W2022350079 cites W2028347191 @default.
- W2022350079 cites W2029502978 @default.
- W2022350079 cites W2041556755 @default.
- W2022350079 cites W2041876783 @default.
- W2022350079 cites W2046149862 @default.
- W2022350079 cites W2049283885 @default.
- W2022350079 cites W2049523071 @default.
- W2022350079 cites W2053628223 @default.
- W2022350079 cites W2059417973 @default.
- W2022350079 cites W2067792404 @default.
- W2022350079 cites W2081986729 @default.
- W2022350079 cites W2089231457 @default.
- W2022350079 cites W2091038119 @default.
- W2022350079 cites W2109182864 @default.
- W2022350079 cites W2162198154 @default.
- W2022350079 doi "https://doi.org/10.1016/j.ygyno.2005.02.004" @default.
- W2022350079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15863169" @default.
- W2022350079 hasPublicationYear "2005" @default.
- W2022350079 type Work @default.
- W2022350079 sameAs 2022350079 @default.
- W2022350079 citedByCount "86" @default.
- W2022350079 countsByYear W20223500792012 @default.
- W2022350079 countsByYear W20223500792013 @default.
- W2022350079 countsByYear W20223500792014 @default.
- W2022350079 countsByYear W20223500792015 @default.
- W2022350079 countsByYear W20223500792016 @default.
- W2022350079 countsByYear W20223500792017 @default.
- W2022350079 countsByYear W20223500792018 @default.
- W2022350079 countsByYear W20223500792019 @default.
- W2022350079 countsByYear W20223500792020 @default.
- W2022350079 countsByYear W20223500792021 @default.
- W2022350079 countsByYear W20223500792022 @default.
- W2022350079 countsByYear W20223500792023 @default.
- W2022350079 crossrefType "journal-article" @default.
- W2022350079 hasAuthorship W2022350079A5015842548 @default.
- W2022350079 hasAuthorship W2022350079A5086072634 @default.
- W2022350079 hasBestOaLocation W20223500791 @default.
- W2022350079 hasConcept C126322002 @default.
- W2022350079 hasConcept C141071460 @default.
- W2022350079 hasConcept C143998085 @default.
- W2022350079 hasConcept C2776694085 @default.
- W2022350079 hasConcept C2776755627 @default.
- W2022350079 hasConcept C2777506904 @default.
- W2022350079 hasConcept C2778119113 @default.
- W2022350079 hasConcept C2779429289 @default.
- W2022350079 hasConcept C2780832733 @default.
- W2022350079 hasConcept C2781059491 @default.
- W2022350079 hasConcept C71924100 @default.
- W2022350079 hasConceptScore W2022350079C126322002 @default.
- W2022350079 hasConceptScore W2022350079C141071460 @default.
- W2022350079 hasConceptScore W2022350079C143998085 @default.
- W2022350079 hasConceptScore W2022350079C2776694085 @default.
- W2022350079 hasConceptScore W2022350079C2776755627 @default.
- W2022350079 hasConceptScore W2022350079C2777506904 @default.
- W2022350079 hasConceptScore W2022350079C2778119113 @default.
- W2022350079 hasConceptScore W2022350079C2779429289 @default.
- W2022350079 hasConceptScore W2022350079C2780832733 @default.
- W2022350079 hasConceptScore W2022350079C2781059491 @default.
- W2022350079 hasConceptScore W2022350079C71924100 @default.
- W2022350079 hasIssue "2" @default.
- W2022350079 hasLocation W20223500791 @default.
- W2022350079 hasLocation W20223500792 @default.
- W2022350079 hasOpenAccess W2022350079 @default.
- W2022350079 hasPrimaryLocation W20223500791 @default.
- W2022350079 hasRelatedWork W1969308974 @default.
- W2022350079 hasRelatedWork W1982921117 @default.
- W2022350079 hasRelatedWork W2058651400 @default.
- W2022350079 hasRelatedWork W2060170707 @default.
- W2022350079 hasRelatedWork W2093344202 @default.
- W2022350079 hasRelatedWork W2252336101 @default.
- W2022350079 hasRelatedWork W2328994372 @default.
- W2022350079 hasRelatedWork W2409428915 @default.
- W2022350079 hasRelatedWork W4238569061 @default.
- W2022350079 hasRelatedWork W4255778788 @default.
- W2022350079 hasVolume "97" @default.
- W2022350079 isParatext "false" @default.
- W2022350079 isRetracted "false" @default.
- W2022350079 magId "2022350079" @default.
- W2022350079 workType "article" @default.